In 9327 Chinese women aged 18–45, an E coli-produced nine-valent HPV vaccine was non-inferior to the bivalent vaccine for HPV 16/18 antibodies and showed 98·2% efficacy against 12-month persistent HPV 31/33/45/52/58 infection; adverse reactions 52·1% vs 42·2%.
RCTn = 9,327
Pan et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial